|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- 08/03/22
- North American rail traffic increased 0.6% for the week ending July 30
- 07/27/22
- North American rail traffic fell 1.4% for the week ending July 23
- 07/20/22
- North American rail traffic fell 1% for the week ending July 16
- 07/13/22
- North American rail traffic rose 1.1% for the week ending July 9
MRSN Mersana Therapeutics - 17:22 Today
- Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056
- 16:35 Today
- Mersana Therapeutics trading resumes
- 16:00 Today
- Mersana Therapeutics trading halted, news pending
- 05/23/22
- Mersana Therapeutics director Hack buys 216K shares of stock
- 17:02 Today
- Lemonade jumps 11% to nearly $28 after Q2 report
- 17:02 Today
- Lemonade jumps 11% to nearly $28 after Q2 report
- 08/01/22
- Lemonade sells Metromile's Enterprise Business Solutions platform to EIS
- 05/10/22
- Lemonade trading resumes
- $127.37 /
-0.695 (-0.54%) - 05/04/22
- Qualys announces $200M increase to share repurchase program
- 05/03/22
- Qualys, White Tuque partner to bolster cybersecurity offerings
- 02/23/22
- Qualys appoints Arjet Skenduli as Chief Accounting Officer
- 06/09/22
- Verona Pharma completes enrollment in Phase 3 ENHANCE-1 trial
- 05/09/22
- Verona Pharma to present successful TQT analysis of ensifentrine
- 16:18 Today
- Turtle Beach concludes proactive outreach to potential buyers
- 05/16/22
- Turtle Beach reaches board refreshment agreement with Donerail Group
- 05/15/22
- Fly Intel: Top five weekend stock stories
- 05/10/22
- Turtle Beach launches Neat Microphones brand in Europe
- 16:46 Today
- Novavax drops 30% to $39.59 after cutting FY22 revenue outlook
- 16:31 Today
- Novavax trading resumes
- 16:00 Today
- Novavax trading halted, news pending
- 08/04/22
- Novavax initiates Phase 2b&3 trial of COVID-19 vaccine in younger children
- 16:03 Today
- Quanterix executive chairman Krusovsky resigns
- 04/22/22
- Quanterix granted Breakthrough Device designation by the FDA for Simoa
- 03/01/22
- Quanterix, Eli Lilly enter Alzheimer's disease diagnosis collaboration
- 03/01/22
- Quanterix CEO Kevin Hrusovsky to become chairman, Masoud Toloue to succeed
- 07/11/22
- TaskUs, Tamil Nadu government sign MoU for Technology Center of Excellence
- 04/19/22
- TaskUs acquires heloo, terms undisclosed
- 03/17/22
- TaskUs announces office expansions in Japan, the U.S.
- 03/09/22
- TaskUs appoints Gonzalez, Greenthal to board expanding it to nine members
- 05/03/22
- DermTech affirms FY22 assay revenue view of $22M-$26M
- 04/28/22
- DermTech announces publication of new GvHD clinical research
- 03/08/22
- DermTech says cost-benefit study published in Journal of Cutaneous Medicine
- 07/27/22
- CarGurus appoints Javier Zamora as general counsel
- 06/06/22
- CarOffer launches PremiumXchange exchange desk
- 05/11/22
- CarGurus announces launch of CarGurus Digital Deal
- 03/28/22
- CarGurus expands CarGurus Instant Max Cash Offer to four more states
- 06/24/22
- Allbirds announces inclusion in Russell 3000 Index
- 05/25/22
- Allbirds sell shoes in select Nordstrom department stores
- 05/22/22
- Fly Intel: Top five weekend stock stories
- 02/17/22
- Allbirds teams with branded recommerce firm Trove to launch 'ReRun'
- 09:03 Today
- 3D Systems appoints Azar II to MAB
- 08:35 Today
- 3D Systems enters agreement to acquire dp polar GmbH
- 08/04/22
- 3D Systems announces Michael Turner hired as CFO
- 07/21/22
- 3D Systems partners with Fleet Space Technologies on RF patch antennas
- 16:35 Today
- Upstart Holdings trading resumes
- 16:00 Today
- Upstart Holdings trading halted, news pending
- 06/08/22
- CFPB issues order to terminate Upstart 'no-action letter'
- 05/16/22
- Third Point lowers stakes in Amazon, Intuit, exits Alphabet position
- 07/21/22
- LivePerson names Jill Layfield as lead independent director
- 07/21/22
- LivePerson announces agreement with Starboard Value
- 07/21/22
- LivePerson announces agreement with Starboard Value
- 06/02/22
- LivePerson 'committed to engaging in constructive dialogue' with Starboard
- 06/22/22
- Freshpet recalls select product due to potential Salmonella contamination
- 16:18 Today
- Trex Company falls 9% to $58.00 after Q2 results, below-consensus guidance
- 06/06/22
- Trex Company provides railing solutions for University of Texas
- 05/16/22
- Trex expands its decking line with introduction of Trex Transcend Lineage
- 04/28/22
- Trex Company debuts Ocula, newest glass windscreen system
- 07/26/22
- Trinseo pauses sale of styrenics business
- 06/30/22
- Trinseo, GMP announce intention to establish Netherlands recycling plant
- 04/27/22
- Trinseo records estimated liability of $36M in styrene monomer E.U. activity
- 02/21/22
- Trinseo appoints Andre Lanning as Chief Commercial Officer
- 17:31 Today
- CorMedix receives CRL from FDA saying that DefenCath NDA cannot be approved
- 05/12/22
- CorMedix believes it has sufficient resources to fund through 1H of 2023
- 05/12/22
- CorMedix announces leadership updates, operational changes
- 04/07/22
- CorMedix announces SAB to support commercialization, pipeline development
- 04/25/22
- Sovos Brands appoints Levine as VP of Investor Relations
- 07/20/22 Barclays
- GoodRx price target lowered to $12 from $15 at Barclays
- 07/18/22 Guggenheim
- GoodRx price target lowered to $13 from $17 at Guggenheim
- 06/22/22 Baird
- GoodRx price target lowered to $6 from $7 at Baird
- 06/13/22 Cowen
- GoodRx price target lowered to $9 from $22 at Cowen
MRSN Mersana Therapeutics - 05/10/22 Baird
- Mersana Therapeutics price target lowered to $18 from $23 at Baird
- 05/09/22 H.C. Wainwright
- Mersana price target lowered to $19 from $24 at H.C. Wainwright
- 11/10/21 Baird
- Mersana Therapeutics price target lowered to $23 from $30 at Baird
- 10/14/21 BTIG
- Mersana Therapeutics assumed with a Buy at BTIG
- 07/18/22 Piper Sandler
- Lemonade downgraded to Neutral from Overweight at Piper Sandler
- 05/11/22 Oppenheimer
- Lemonade price target lowered to $30 from $45 at Oppenheimer
- 05/11/22 JMP Securities
- Lemonade price target lowered to $40 from $95 at JMP Securities
- 02/25/22 Barclays
- Lemonade price target lowered to $22 from $43 at Barclays
- $127.37 /
-0.695 (-0.54%) - 07/26/22 Truist
- Qualys price target raised to $125 from $115 at Truist
- 07/15/22 DA Davidson
- Qualys initiated with a Neutral at DA Davidson
- 04/11/22 Wolfe Research
- Qualys initiated with an Outperform at Wolfe Research
- 04/11/22 Wolfe Research
- Qualys initiated with an Outperform at Wolfe Research
- 06/17/22 Wedbush
- Verona Pharma price target lowered to $18 from $25 at Wedbush
- 09/13/21
- Fly Intel: Top five analyst initiations
- 09/13/21 H.C. Wainwright
- Verona Pharma initiated with a Buy at H.C. Wainwright
- 08/04/22 Wedbush
- Turtle Beach price target lowered to $22 from $27 at Wedbush
- 07/06/22 DA Davidson
- Turtle Beach price target lowered to $25 from $30 at DA Davidson
- 05/17/22 Wedbush
- Wedbush upgrades Turtle Beach to Outperform on higher chance of deal
- 05/17/22 Wedbush
- Turtle Beach upgraded to Outperform from Neutral at Wedbush
- 07/22/22 B. Riley
- Novavax price target lowered to $171 from $181 at B. Riley
- 06/08/22 B. Riley
- B. Riley sees front line status for Novavax vaccine as mRNA alternative
- 06/08/22 Cowen
- Novavax positive advisory vote removes major overhang, says Cowen
- 06/08/22 Cantor Fitzgerald
- Novavax price target raised to $168 from $146 at Cantor Fitzgerald
- 05/11/22 Cowen
- Quanterix price target lowered to $38 from $60 at Cowen
- 03/15/22 BTIG
- Quanterix price target lowered to $60 from $92 at BTIG
- 03/02/22 Goldman Sachs
- Quanterix upgraded to Neutral from Sell at Goldman Sachs
- 10/14/21 Cowen
- Quanterix coverage transferred at Cowen
- 07/20/22 JPMorgan
- TaskUs price target lowered to $35 from $41 at JPMorgan
- 07/19/22 Citi
- TaskUs initiated with a Buy at Citi
- 06/30/22 Morgan Stanley
- TaskUs price target lowered to $28 from $35 at Morgan Stanley
- 05/10/22 BTIG
- TaskUs price target lowered to $45 from $60 at BTIG
- 07/18/22 Oppenheimer
- DermTech assumed with an Outperform at Oppenheimer
- 05/09/22 BTIG
- DermTech transferred with a Buy at BTIG
- 05/04/22 Cowen
- DermTech price target lowered to $20 from $33 at Cowen
- 04/18/22 BTIG
- DermTech price target lowered to $38 from $48 at BTIG
- 07/25/22 Truist
- CarGurus price target lowered to $44 from $53 at Truist
- 06/30/22 JMP Securities
- CarGurus resumed with a Market Perform at JMP Securities
- 06/21/22 BTIG
- CarGurus price target lowered to $33 from $40 at BTIG
- 05/10/22 RBC Capital
- CarGurus price target lowered to $45 from $56 at RBC Capital
- 07/22/22 Piper Sandler
- Allbirds transferred with Overweight at Piper Sandler
- 07/21/22 KeyBanc
- KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
- 07/20/22 KeyBanc
- Allbirds initiated with a Sector Weight at KeyBanc
- 07/20/22 Stifel
- Stifel downgrades trio of Sports and Lifestyle Brands to Hold
- 05/11/22 Craig-Hallum
- 3D Systems price target lowered to $10 from $18 at Craig-Hallum
- 05/10/22 BofA
- 3D Systems price target lowered to $12 from $23 at BofA
- 03/01/22 Craig-Hallum
- 3D Systems price target lowered to $18 from $33 at Craig-Hallum
- 03/01/22 B. Riley
- 3D Systems price target lowered to $22 from $24 at B. Riley
- 07/22/22 Morgan Stanley
- Berkshire Hills halting additions of new Upstart loans, says Morgan Stanley
- 07/18/22 Piper Sandler
- Upstart price target lowered to $25 from $44 at Piper Sandler
- 07/17/22 Barclays
- Upstart price target lowered to $25 from $35 at Barclays
- 07/15/22 Morgan Stanley
- Upstart price target lowered to $15.50 from $19 at Morgan Stanley
- 07/26/22 Jefferies
- LivePerson price target lowered to $15 from $18 at Jefferies
- 05/23/22 Jefferies
- LivePerson price target lowered to $18 from $23 at Jefferies
- 05/10/22 B. Riley
- LivePerson price target lowered to $19 from $23 at B. Riley
- 05/10/22 Mizuho
- LivePerson price target lowered to $18 from $20 at Mizuho
- 05/20/22 Atlantic Equities
- Atlantic Equities sees more volatility for Freshpet, downgrades shares
- 05/20/22 Atlantic Equities
- Freshpet downgraded to Neutral from Overweight at Atlantic Equities
- 05/03/22 Cowen
- Freshpet price target lowered to $163 from $181 at Cowen
- 05/03/22 Oppenheimer
- Freshpet price target lowered to $110 from $120 at Oppenheimer
- 07/15/22 JPMorgan
- Trex Company price target lowered to $54 from $66 at JPMorgan
- 07/14/22 Barclays
- Trex Company price target lowered to $63 from $68 at Barclays
- 06/08/22 JPMorgan
- Azek valuation remains attractive versus Trex, says JPMorgan
- 06/03/22 Barclays
- Barclays continues to prefer Azek shares over Trex
- 07/27/22 Deutsche Bank
- Trinseo price target lowered to $42 from $52 at Deutsche Bank
- 07/14/22 Deutsche Bank
- Trinseo named short-term buy idea at Deutsche Bank
- 06/16/22 Jefferies
- Trinseo price target lowered to $54 from $70 at Jefferies
- 05/16/22 Deutsche Bank
- Trinseo price target lowered to $52 from $60 at Deutsche Bank
- 03/30/22 UBS
- Sovos Brands initiated with a Buy at UBS
- 10/18/21 BofA
- Sovos Brands initiated with a Buy at BofA
- 10/18/21 Telsey Advisory
- Sovos Brands initiated with an Outperform at Telsey Advisory
- 10/18/21 Cowen
- Cowen starts Rao's owner Sovos Brands at Outperform with $20 target
- 16:13 Today
- GoodRx sees Q3 revenue roughly $185M, consensus $201.4M
- 16:12 Today
- GoodRx reports Q2 adjusted EPS 6c, consensus 4c
- 12:53 Today
- Notable companies reporting after market close
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/10/22
- FreightCar America sees FY22 revenue $320M-$340M
- 05/10/22
- FreightCar America reports Q1 EPS ($1.11) vs ($1.96) last year
- 03/22/22
- FreightCar America reports Q4 EPS 6c vs (87c) last year
MRSN Mersana Therapeutics - 16:24 Today
- Mersana Therapeutics reports Q2 EPS (55c), consensus (52c)
- 05/09/22
- Mersana Therapeutics reports Q1 EPS (59c), consensus (32c)
- 02/28/22
- Mersana Therapeutics reports Q4 EPS (68c), consensus (67c)
- 16:57 Today
- Lemonade raises FY22 revenue view to $236M-$239M, consensus $213.41M
- 16:56 Today
- Lemonade sees Q3 revenue $63M-$65M, consensus $56.97M
- 16:55 Today
- Lemonade reports Q2 EPS ($1.10), consensus ($1.32)
- 05/09/22
- Lemonade sees FY22 revenue $205M-$208M, consensus $216.49M
- $127.37 /
-0.695 (-0.54%) - 16:42 Today
- Qualys raises FY22 non-GAAP EPS view to $3.50-$3.55 from $3.13-$3.17
- 16:40 Today
- Qualys sees Q3 non-GAAP EPS 85c-87c from 86c last year
- 16:38 Today
- Qualys reports Q2 non-GAAP EPS 89c, consensus 80c
- 05/04/22
- Qualys raises FY22 adjusted EPS view to $3.13-$3.17 from $2.87-$2.92
- 16:13 Today
- Turtle Beach sees FY22 EPS ($1.35) to (90c), consensus 89c
- 16:11 Today
- Turtle Beach reports Q2 EPS ($1.08), consensus (38c)
- 05/04/22
- Turtle Beach backs FY22 EPS view 70c-$1.20, consensus 89c
- 05/04/22
- Turtle Beach reports Q1 adjusted EPS (39c), consensus (52c)
- 16:45 Today
- Novavax cuts FY22 revenue view to $2B-$2.3B from $4B-$5B, consensus $4.27B
- 16:09 Today
- Novavax revised FY22 revenue guidance to $2B-$2.3B
- 16:06 Today
- Novavax reports Q2 EPS ($6.53) vs. ($4.75) last year
- 05/09/22
- Novavax backs FY22 revenue view $4B-$5B, consensus $4.49B
- 16:05 Today
- Quanterix reports Q2 revenue $23.5M, consensus $30.1M
- 05/10/22
- Quanterix reports Q1 net loss $18.2M vs.$10.1M loss last year
- 03/01/22
- Quanterix reports Q4 revenue $30.29M, consensus $28.49M
- 16:21 Today
- TaskUs reports Q2 adjusted EPS 38c vs 32c last year
- 05/09/22
- TaskUs reaffirms FY22 revenue view $980M-$1.0B, consensus $993.43M
- 05/09/22
- TaskUs sees Q2 revenue $241.5M-$243.5M, consensus $239.39M
- 05/09/22
- TaskUs reports Q1 adjusted EPS 34c, consensus 32c
- 16:07 Today
- DermTech reports Q2 EPS (99c), consensus ($1.01)
- 05/03/22
- DermTech reports Q1 EPS ($1.01), consensus (89c)
- 03/01/22
- DermTech sees FY22 revenue $22M-$26M, consensus $24.2M
- 03/01/22
- DermTech sees Q1 revenue $3.4M-$3.8M, consensus $4.25M
- 16:06 Today
- CarGurus sees Q3 EPS 25c-28c, consensus 33c
- 16:04 Today
- CarGurus reports Q2 EPS 32c, consensus 31c
- 12:53 Today
- Notable companies reporting after market close
- 05/25/22
- CarGurus now sees Q2 adjusted EPS 27c-30c vs. prior 26c-29c view
- 16:43 Today
- Allbirds sees FY22 revenue $305M-$315M , consensus $339.62M
- 16:41 Today
- Allbirds sees Q3 revenue $65M-$70M , consensus $77.93M
- 16:38 Today
- Allbirds reports Q2 EPS (12c), consensus (16c)
- 12:53 Today
- Notable companies reporting after market close
- 05/09/22
- 3D Systems sees FY22 revenue $580M-$625M, consensus $595.48M
- 05/09/22
- 3D Systems reports Q1 EPS (6c), consensus 0c
- 04/25/22
- 3D Systems backs FY22 revenue view of $570M-$630M, consensus $596M
- 02/28/22
- 3D Systems reports Q4 EPS 9c, consensus 4c
- 16:38 Today
- Upstart sees Q3 revenue $170M, consensus $248.92M
- 16:36 Today
- Upstart reports Q2 adjusted EPS 1c, consensus 10c
- 12:53 Today
- Notable companies reporting after market close
- 07/07/22
- Upstart cuts Q2 revenue view to $228M from $295M-$305M, consensus $297.68M
- 16:49 Today
- LivePerson lowers FY22 revenue view to $507.1M-$518.3M from $544.8M-$563.3M
- 16:46 Today
- LivePerson sees Q3 revenue $120.5M-$123.6M, consensus $140.45M
- 16:45 Today
- LivePerson reports Q2 EPS (98c), consensus (17c)
- 05/09/22
- LivePerson reaffirms FY22 revenue view $544.8N-$563.3M, consensus $553.44M
- 17:27 Today
- Freshpet backs FY22 revenue view of at least $575M, consensus $582.72M
- 17:25 Today
- Freshpet reports Q2 EPS (45c), consensus (14c)
- 05/02/22
- Freshpet backs FY22 revenue view at least $575M, consensus $576.99M
- 05/02/22
- Freshpet reports Q1 EPS (40c), consensus (39c)
- 16:18 Today
- Trex Company sees Q3 revenue $180M-$190M, consensus $355.0M
- 16:16 Today
- Trex Company reports Q2 EPS 79c, consensus 68c
- 05/09/22
- Trex Company backs FY22 revenue growth view of double-digits, consensus $1.38B
- 05/09/22
- Trex Company sees Q2 revenue $375M-$385M, consensus $376.52M
- 16:34 Today
- Trinseo sees FY22 adjusted EBITDA $475M-$525M
- 16:31 Today
- Trinseo reports Q2 adjusted EPS $1.79 vs $3.70 last year
- 05/04/22
- Trinseo lowers FY22 adjusted EBITDA view $625M-$675M from $700M-$750M
- 05/04/22
- Trinseo reports Q1 EPS $2.08, consensus $1.66
- 05/12/22
- CorMedix reports Q1 EPS (18c), consensus (22c)
- 03/29/22
- CorMedix reports Q4 EPS (20c), consensus (23c)
- 08/03/22
- Sovos Brands raises FY22 revenue view to $825-$835M, consensus $814.4M
- 08/03/22
- Sovos Brands reports Q2 adjusted EPS 13c, consensus 8c
- 05/04/22
- Sovos Brands backs FY22 revenue view $800M-$815M, consensus $810.62M
- 05/04/22
- Sovos Brands reports Q1 adjusted EPS 14c, consensus 12c
|
